Inspirational chemistry of bioabsorbable long-acting injectables

被引:0
|
作者
Thomas Tice
机构
[1] Evonik Corporation,
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Long-acting injectables (LAIs) have made a tremendous impact on clinical medicine. As evidence, dozens of approved LAI products are on the market. These LAI successes, in a large part, came from the clever chemistry of their materials that control drug delivery performance. Beyond their materials, what innovations and technologies led to LAI success? What were the scientific progressions and who were the people and their stories behind LAI success? The answers to these questions are interesting to hear about, learn from, and be inspired by. Many people from many diverse fields contributed to the scientific advancement, product development, and product launches of long-acting injectables. Over 50 years ago, LAI pioneers envisioned a host of new drug delivery concepts and engaged their enthusiasm to reduce their concepts to practice. In doing so, they considered a variety of materials, dosage forms, routes of administration, and manufacturing processes, and they had to devise new tools to support product development. Because of the wide technology breadth of long-acting injectables, this publication focuses on bioabsorbable LAIs formulated with polymeric excipients such as lactide/glycolide functional excipients. Their historical progression of polymer chemistry and formulation development is shared. Successes are highlighted with some backstories.
引用
收藏
页码:371 / 377
页数:6
相关论文
共 50 条
  • [11] Free long-acting injectables for patients with psychosis: A step forward
    Kong, Ling-zhuo
    Shen, Yu-ting
    Zhang, Dan-hua
    Lai, Jian-bo
    Hu, Shao-hua
    ASIAN JOURNAL OF PSYCHIATRY, 2023, 83
  • [12] Long-Acting Ocular Injectables: Are We Looking In The Right Direction?
    Dang, Mickael
    Shoichet, Molly S.
    ADVANCED SCIENCE, 2024, 11 (08)
  • [13] The use of long-acting injectables in early-phase schizophrenia 
    Tiihonen, Jari
    LANCET PSYCHIATRY, 2023, 10 (07): : 481 - 482
  • [14] Long-acting injectables for tuberculosis prophylaxis and treatment: is now the time?
    Dooley, Kelly E.
    INTERNATIONAL JOURNAL OF TUBERCULOSIS AND LUNG DISEASE, 2018, 22 (08) : 833 - 834
  • [15] Long-Acting Injectables: A Strategy to Mitigate Nonadherence in Bipolar Disorder
    Faden, Justin
    Maymind, Elina
    BIPOLAR DISORDERS, 2025,
  • [16] Improving patient acceptance of maintenance treatment with long-acting injectables
    Potkin, S.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S617 - S617
  • [17] Short-acting antipsychotics or long-acting injectables? A treatment comparison in patients with schizophrenia
    Thiem, Helena
    Folkerts, Here
    Voelkel, Lukas
    GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2020, 25 (03): : 170 - 178
  • [18] Clozapine, Long-Acting Injectables (and Polypharmacy?) Superior in US and International Registries
    Leucht, Stefan
    Tiihonen, Jari
    AMERICAN JOURNAL OF PSYCHIATRY, 2021, 178 (10): : 888 - 889
  • [19] "Ajudar" - a practice with people with mental disorders treated with long-acting injectables
    Ferreira, M. Cabral
    Magalhaes, C. M.
    Silva, F.
    Basto, F.
    EUROPEAN JOURNAL OF PUBLIC HEALTH, 2024, 34
  • [20] Lipid based intramuscular long-acting injectables: Current state of the art
    Wilkinson, Janine
    Ajulo, Damilola
    Tamburrini, Valeria
    Gall, Gwenaelle Le
    Kimpe, Kristof
    Holm, Rene
    Belton, Peter
    Qi, Sheng
    EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2022, 178